Related references
Note: Only part of the references are listed.Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
Jesus Moro-Alvarez
Clinical Interventions in Aging (2016)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Pharmacologic treatment to prevent fractures: from markers to patients Pierre Delmas
Steven R. Cummings
OSTEOPOROSIS INTERNATIONAL (2009)
Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease
Lori Mosca et al.
STROKE (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis
Pauline M. Camacho et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2008)
Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy - Reply
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
S. Boonen et al.
JOURNAL OF INTERNAL MEDICINE (2008)
FRAX™ and the assessment of fracture probability in men and women from the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Common mistakes in the clinical use of bone mineral density testing
E. Michael Lewiecki et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2008)
Compliance and persistence with osteoporosis therapies
Stuart L. Silverman et al.
Current Rheumatology Reports (2008)
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
Paul D. Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Loss of treatment benefit due to low compliance with bisphosphonate therapy
F. J. A. Penning-van Beest et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Phase III double-blind trial of Arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer
VijayaLaxmi Deshmane et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis
E. Michael Lewiecki
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis
Benjamin M. P. Tang et al.
LANCET (2007)
Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis
O. Gajic-Veljanoski et al.
OSTEOPOROSIS INTERNATIONAL (2007)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial
Joan M. Lappe et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2007)
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis
Deborah T. Gold et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Safety considerations with bisphosphonates for the treatment of osteoporosis
William Strampel et al.
DRUG SAFETY (2007)
Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys
Cynthia Lees et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2007)
Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
E. Seeman
BONE (2007)
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women
Ellewellyn G. Pasion et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2007)
Patient adherence to osteoporosis medications - Problems, consequences and management strategies
Alexandra Papaioannou et al.
DRUGS & AGING (2007)
Selective estrogen receptor modulators for postmenopausal osteoporosis - Current state of development
Luigi Gennari et al.
DRUGS & AGING (2007)
Osteoporosis prevention and therapy: preserving and building strength through bone quality
M. Kleerekoper
OSTEOPOROSIS INTERNATIONAL (2006)
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France
Joyce A. Cramer et al.
CLINICAL THERAPEUTICS (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
Elizabeth Barrett-Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor β and androgen receptor in rats
Xiao-Ning Wang et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2006)
A meta-analysis of the association between adherence to drug therapy and mortality
Scot H. Simpson et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
Janne Komi et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting
Timothy W. Downey et al.
SOUTHERN MEDICAL JOURNAL (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene
Michael R. McClung et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2006)
Persistence with bisphosphonate treatment for osteoporosis: Finding the root of the problem
JA Cramer et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Calcium plus vitamin D supplementation and the risk of fractures
RD Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis
E Seeman et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis
FJA Penning-van Beest et al.
CLINICAL THERAPEUTICS (2006)
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease
Raja S. Bobba et al.
DRUG SAFETY (2006)
Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study
Pierre D. Delmas et al.
ARTHRITIS AND RHEUMATISM (2006)
Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture
Kousuke Iba et al.
JOURNAL OF ORTHOPAEDIC SCIENCE (2006)
Compliance with osteoporosis medications
DH Solomon et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity
BS Komm et al.
ENDOCRINOLOGY (2005)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women
S Ronkin et al.
OBSTETRICS AND GYNECOLOGY (2005)
Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial
AM Grant et al.
LANCET (2005)
Hip fracture in women without osteoporosis
SA Wainwright et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
JY Reginster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D) for prevention of fractures in primary care
J Porthouse et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Secondary prevention of hip fractures among the hospitalized elderly - Are we doing enough?
HK Kamel
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2005)
Underdiagnosis of vertebral fractures is a worldwide problem: The IMPACT study
PD Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Epidemiology of osteoporotic fractures
Olof Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark
P Vestergaard et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Effect of vitamin D on falls - A meta-analysis
HA Bischoff-Ferrari et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
GL Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats
HZ Ke et al.
ENDOCRINOLOGY (2004)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women
J Komi et al.
GYNECOLOGICAL ENDOCRINOLOGY (2004)
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled
JA Clowes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice:: An open-label, prospective, nonrandomized, observational study
C Turbi et al.
CLINICAL THERAPEUTICS (2004)
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
PJ Meunier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial
E Barrett-Connor et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Compliance with drug therapies for the treatment and prevention of osteoporosis
JS McCombs et al.
MATURITAS (2004)
Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial
JA Cauley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial
EM Rutanen et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2003)
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients
J Baselga et al.
ANNALS OF ONCOLOGY (2003)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer
A Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of vitamin D and calcium supplementation on falls:: A randomized controlled trial
HA Bischoff et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats
YFL Ma et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A Randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
JJ Body et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study
SR Goldstein et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2002)
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
JP Brown et al.
CALCIFIED TISSUE INTERNATIONAL (2002)
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
PD Delmas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
D Grady et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
S Hulley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
IR Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Combined calcium and vitamin D-3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study
MC Chapuy et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Mechanisms of action and therapeutic potential of strontium in bone
PJ Marie et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy
P Alexandersen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Risk of new vertebral fracture in the year following a fracture
R Lindsay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
CM Klotzbuecher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
CH Chesnut et al.
AMERICAN JOURNAL OF MEDICINE (2000)
Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women
M Pfeifer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Risk of mortality following clinical fractures
JA Cauley et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
